Last updated on March 2016

Phase 1 Combination Study of MM-151 and MM-121


Brief description of study

This is a Phase 1 open-label, dose-escalation trial using "3+3" design, evaluating MM-151 co-administration with MM-121 at varying dose levels.

Detailed Study Description

This is a two-part Phase 1, non-randomized, open-label study of MM-151 plus MM-121 in patients with advanced, heregulin-positive lung, head and neck, and colorectal cancers. In part 1 of the study cohorts of 3 or more patients will be treated at escalating doses of MM-151 in combination with MM-121 until a maximum tolerated combination dose is identified. In part 2 of the study, patients with be treated with combination dose identified in part 1 of the study.

Clinical Study Identifier: NCT02538627

Find a site near you

Start Over

University of Colorado

Aurora, CO United States
  Connect »

Northwestern

Chicago, IL United States
  Connect »

Vanderbilt

Nashville, TN United States
  Connect »